PWMG
TEVA icon

Prestige Wealth Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

Prestige Wealth Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-174
Closed -$1K – 1048
2021
Q4 		$1K Hold
174
– – ﹤0.01% 955
2021
Q3 		$2K Hold
174
– – ﹤0.01% 828
2021
Q2 		$2K Sell
174
-50
-22% -$529 ﹤0.01% 827
2021
Q1 		$3K Hold
224
– – ﹤0.01% 747
2020
Q4 		$2K Sell
224
-300
-57% -$2.87K ﹤0.01% 789
2020
Q3 		$5K Hold
524
– – ﹤0.01% 548
2020
Q2 		$7K Hold
524
– – ﹤0.01% 480
2020
Q1 		$5K Hold
524
– – ﹤0.01% 499
2019
Q4 		$5K Hold
524
– – ﹤0.01% 429
2019
Q3 		$4K Hold
524
– – ﹤0.01% 443
2019
Q2 		$5K Sell
524
-84
-14% -$1.01K ﹤0.01% 404
2019
Q1 		$10K Sell
608
-37
-6% -$652 0.01% 337
2018
Q4 		$10K Buy
+645
New +$13.2K 0.01% 437

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Prestige Wealth Management Group's TEVA Position: Q1 2022 in Review

Prestige Wealth Management Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 174 shares — an estimated $1K sold.

Prestige Wealth Management Group first reported a position in TEVA in Q4 2018 and held it in 13 quarters. The position peaked at $10K in Q1 2019. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Prestige Wealth Management Group reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Prestige Wealth Management Group sold 174 Teva Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Prestige Wealth Management Group first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 13 quarters.
  • Prestige Wealth Management Group's Teva Pharmaceuticals position peaked at $10K in Q1 2019.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Prestige Wealth Management Group's 13F filing for Q1 2022, filed 5 May 2022.